CD4 Decline Is Associated With Increased Risk of Cardiovascular Disease, Cancer, and Death in Virally Suppressed Patients With HIV
Authors:
Open Access
- 10 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (2) , 314-321
Abstract
Background. The clinical implications of a considerable CD4 decline despite antiretroviral treatment and viral suppression are unknown. We aimed to test the hypothesis that a major CD4 decline could be a marker of cardiovascular disease or undiagnosed cancer. Methods. Patients with human immunodeficiency virus (HIV) were followed in the Danish nationwide, population-based cohort study in the period 1995–2010 with quarterly CD4 measurements. Associations between a CD4 decline of ≥30% and cardiovascular disease, cancer, and death were analyzed using Poisson regression with date of CD4 decline as a time-updated variable. Results. We followed 2584 virally suppressed HIV patients for 13 369 person-years (PY; median observation time, 4.7 years). Fifty-six patients developed CD4 decline (incidence rate, 4.2/1000 PY [95% confidence interval {CI}, 3.2–5.4]). CD4 counts dropped from a median of 492 cells/µL to 240 cells/µL. CD8, CD3, and total lymphocyte counts dropped concomitantly. No HIV-related factors, apart from treatment with didanosine, were associated with CD4 decline. The risk of cardiovascular disease, cancer, and death increased markedly ≤6 months after CD4 decline (incidence rate ratio, 11.7 [95% CI, 3.6–37.4] and 13.7 [95% CI, 4.3–43.6], respectively, and mortality rate ratio 4.3 [95% CI, 1.1–17.6]). Conclusion. A major decline in CD4 count is associated with a marked increased risk of cardiovascular disease, cancer, and death among virally suppressed HIV patients.Keywords
This publication has 18 references indexed in Scilit:
- Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter CohortsClinical Infectious Diseases, 2012
- Low Lymphocyte Count and Cardiovascular DiseasesCurrent Medicinal Chemistry, 2011
- HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytesBlood, 2011
- CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy eraAIDS, 2010
- Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapyAIDS, 2010
- Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromesEuropean Journal of Internal Medicine, 2009
- HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cellsProceedings of the National Academy of Sciences, 2008
- Cohort Profile: The Danish HIV Cohort StudyInternational Journal of Epidemiology, 2008
- Efficacy of Cancer Chemotherapy in Relation to the Pretreatment Number of Lymphocytes in Patients with Metastatic Solid TumorsThe International Journal of Biological Markers, 2004
- The dynamics of CD4+ T-cell depletion in HIV diseaseNature, 2001